# Diego Villa Clé

Source: https://onco.cc/people/diego-villa-cle/  
OnCo record `diego-villa-cle` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A haematologist at the University of São Paulo in Ribeirão Preto who leads the clinical trial of Brazil's own CAR-T cell therapy.

## Summary

Diego Villa Clé is the principal investigator of CARTHEDRALL (NCT06101381), the multicentre phase 1/2 trial of the academic CD19-directed CAR-T cell made at the University of São Paulo's Ribeirão Preto campus; ClinicalTrials.gov gives his affiliation as the Ribeirão Preto Medical School and his title as medical coordinator. He is senior author of the 2024 Bone Marrow Transplantation report of the first 20 patients treated with the product from 2019 to 2023, and first author of the 2021 Brazilian Association of Haematology, Haemotherapy and Cell Therapy consensus on structuring centres to give CAR-T therapy.

## Fields

- Kind: Person
- Last checked: 2026-11-03
- Tags: clinician-scientist; cell-therapy
- Role: Haematologist; principal investigator and medical coordinator of the CARTHEDRALL CAR-T trial, Ribeirão Preto Medical School, University of São Paulo
- Specialisms: CAR-T cell therapy; Haematopoietic cell transplantation; Lymphoma and acute lymphoblastic leukaemia

## Sources

- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Cl%C3%A9%20DV%5Bau%5D
- ClinicalTrials.gov: NCT06101381: https://clinicaltrials.gov/study/NCT06101381

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- institutions: [Fundação Hemocentro de Ribeirão Preto](https://onco.cc/institutions/hemocentro-ribeirao-preto/)
- trials: [CD19-directed CAR-T cell therapy for refractory or relapsed acute lymphoblastic leukaemia or non-Hodgkin lymphoma (CARTHEDRALL)](https://onco.cc/trials/nct06101381/)
- key papers: [Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil](https://onco.cc/key-papers/paper-donadel-academic-cart19-brazil-bmt-2024/)

---
JSON: https://onco.cc/api/v1/entities/diego-villa-cle.json